Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
National Institutes of Health Clinical Center (CC)
European Myeloma Network B.V.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
University of California, San Francisco
Celgene
Essen Biotech
M.D. Anderson Cancer Center